An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

NCT06498921 · clinicaltrials.gov ↗

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer

Interventions

OTHER: Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel

Sponsor

Bayer